These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33669443)

  • 1. Roles of Ceramides in Non-Alcoholic Fatty Liver Disease.
    Hajduch E; Lachkar F; Ferré P; Foufelle F
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingolipid metabolism in non-alcoholic fatty liver diseases.
    Régnier M; Polizzi A; Guillou H; Loiseau N
    Biochimie; 2019 Apr; 159():9-22. PubMed ID: 30071259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease.
    Zhu C; Huai Q; Zhang X; Dai H; Li X; Wang H
    Int J Biol Sci; 2023; 19(1):311-330. PubMed ID: 36594091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives.
    Yu XD; Wang JW
    Biochem Pharmacol; 2022 Aug; 202():115157. PubMed ID: 35777449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease.
    Jiang M; Li C; Liu Q; Wang A; Lei M
    Front Endocrinol (Lausanne); 2019; 10():665. PubMed ID: 31616384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipidomics in non-alcoholic fatty liver disease.
    Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
    World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
    Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
    Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.
    Kurek K; Piotrowska DM; Wiesiołek-Kurek P; Łukaszuk B; Chabowski A; Górski J; Zendzian-Piotrowska M
    Liver Int; 2014 Aug; 34(7):1074-83. PubMed ID: 24106929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.
    Xu Y; Guo W; Zhang C; Chen F; Tan HY; Li S; Wang N; Feng Y
    Front Pharmacol; 2020; 11():601. PubMed ID: 32477116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin E alleviates non-alcoholic fatty liver disease in phosphatidylethanolamine N-methyltransferase deficient mice.
    Presa N; Clugston RD; Lingrell S; Kelly SE; Merrill AH; Jana S; Kassiri Z; Gómez-Muñoz A; Vance DE; Jacobs RL; van der Veen JN
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):14-25. PubMed ID: 30300671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable Isotope-Labeled Lipidomics to Unravel the Heterogeneous Development Lipotoxicity.
    Shih LM; Tang HY; Lynn KS; Huang CY; Ho HY; Cheng ML
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30400243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingolipids at the Crossroads of NAFLD and Senescence.
    Nikolova-Karakashian M
    Adv Cancer Res; 2018; 140():155-190. PubMed ID: 30060808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans.
    Apostolopoulou M; Gordillo R; Gancheva S; Strassburger K; Herder C; Esposito I; Schlensak M; Scherer PE; Roden M
    BMJ Open Diabetes Res Care; 2020 Nov; 8(2):. PubMed ID: 33219119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.